Multiple Myeloma
Conditions
Keywords
Value-base health care, e-coach, adherence
Brief summary
A two-arm open-label parallel-group randomized controlled trial will be conducted to compare the telemonitoring (MM e-coach) with standard MM care. This study aimed to recruit 150 patients with recently diagnosed multiple myeloma (RDMM), starting first or second line of treatment. Blinded primary outcome is adherence by pill count after start of treatment at 1-3 months. Secondary outcomes are patient reported outcomes: Groninger frailty index (GFI), quality of life (EQ-5D-5L, EORTC-QLQ-C30), shared decision making (SDM-Q-9), self-reported adherence (MARS-5), single item questions, patient experiences (PREMs), adverse events, overall survival (OS) and progression free survival (PFS). Patient reported outcomes were developed and integrated in the e-coach MM to regularly measure digitized outcomes of MM patients from time of RDMM until 12 months post-diagnosis. Online measurements will be performed at baseline (0), 3, 6, 9 and 12 months.
Interventions
DEVICEe-coach multipel myeloma (MM)
In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
Sponsors
Isala
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Caregiver)
Masking description
pill count
Intervention model description
A two-arm open-label parallel-group randomized controlled trial (RCT) will be conducted at a supra regional cancer center (referred to as 'het oncologisch centrum Isala'), which provides hematology services to a population with 0.5 million adherence and a population of 1 million referral, in the Northern-East region of The Netherlands.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible to participate in this study, a participant (patient) must meet all of the -following criteria: * signed informed consent * \>18 years * recently diagnosed MM patients with first-line or second-line treatment * able to complete patient-reported outcome measures and experiences * have minimal digital skills to check if they are able to interact with an e-coach * can read and understand Dutch. Participants who meet any of the following criteria will be excluded from participation in this study * psychiatric illness requiring secondary-care intervention * too ill to engage with the intervention in the opinion of the clinical care team * no perspective of \>12 months survival.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blinded primary outcome by pill count | over a time periode of 3 months |
Countries
Netherlands
Contacts
Primary ContactJob Eijsink, PharmD
Backup ContactPeter ter Horst, PharmD,PhD
Outcome results
None listed